Video
Dr. Garmezy on impact of antibody-drug conjugates on bladder cancer treatment paradigm
Author(s):
“What’s really exciting over the next few years is how are these antibody-drug conjugates that are already FDA-approved going to partner with other current drugs that we can use to treat this disease, such as immunotherapy,” says Garmezy.
Benjamin Garmezy, MD, discusses the FDA-approved antibody-drug conjugates (ADCs) enfortumab vedotin (Padcev) and sacituzumab govitecan (Trodelvy) and the next steps with ADCs in the treatment paradigm for patients with urothelial carcinoma.
Garmezy is assistant director of Genitourinary Research at Sarah Cannon Research Institute at Tennessee Oncology.
Related Videos
Related Content
